The grandfather also explained that he was late for his appointment because he couldn’t find a parking spot, but staff were happy to see him regardless.
The December interview was shared widely online with Mr Kenyon praised as a “national treasure” and the segment described as “peak British” by Jeremy Vine.
Today, the grandfather revealed the immunity granted by his second jab meant he could now hug his “enchanting” two grandchildren.
He told The Guardian: “When I went to get the first one, I was the only person there, I think. There was one man there, with a pencil and some paper and writing down a few names. This time it was very different. Very efficient.”
He added: “This time, I was able to park absolutely outside the main building in a special slot. So, all was well. It was very painless.
“Now, I don’t have to think about it again. It’s all done. I am going to survive.”
Mr Kenyon’s immunity comes as Dame Esther Rantzen has said she is “so glad and so relieved” her second shot of the coronavirus vaccine has been delayed, allowing someone else to have an initial dose.
The Childline founder, aged “80 and a half”, said “I really want my second jab to protect somebody who needs it more than me” and underlined how “precious” it is to have an extra level of defence against the virus.
The UK’s chief medical officers have said the first Covid-19 vaccine dose offers “substantial” protection, and vaccine dose schedules have been altered so more people can have their first jab.
Rather than providing the required two doses in as short a time as possible, the second dose of both the Oxford/AstraZeneca and the Pfizer/BioNTech vaccines will now be within 12 weeks of the first.
Health Secretary Matt Hancock said on Monday that he was “incredibly worried” about the threat posed by the variant, which has added to problems already created by another variant that was discovered in Kent and which has increased UK cases by up to 70 per cent.
Research is under way at Porton Down laboratory to determine whether the variants could render the Pfizer or Oxford vaccines less effective, with preliminary results expected next week.